First-of-its-Kind Cyclic IMS Provides Unlimited
Experimental Opportunities while the Research-Grade SYNAPT XS
Brings Analytical Flexibility
Waters Corporation (NYSE:WAT) today unveiled two new high
resolution mass spectrometry systems addressing the most
challenging analytical needs of leading R&D scientists at the
67th Conference on Mass Spectrometry and Allied
Topics (ASMS), June 2 – 6 in Atlanta.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190530005814/en/
The Waters SELECT SERIES Cyclic IMS
seamlessly integrates cyclic ion mobility (cIM) technology into a
high performance research-grade time-of-flight mass spectrometer
providing limitless experimental potential. (Photo: Business
Wire)
The first-of-its-kind Waters™ SELECT SERIES Cyclic™ IMS
seamlessly integrates cyclic ion mobility (cIM) technology into a
high performance research-grade time-of-flight mass spectrometer
providing limitless experimental potential. Combining novel IMS
capability with significantly improved mass spectrometry (MS)
performance and enabling software, this platform allows leading
researchers to unlock the potential in scientific discovery.
The SYNAPT™ XS is a new highly flexible, high resolution mass
spectrometer for R&D labs focused on discovery applications
which need the greatest variety of analytical strategies to tackle
inherently challenging questions. By providing high-levels of
flexibility through inlets and acquisition modes, the SYNAPT XS
delivers greater freedom of analytical choice to support scientific
creativity and technical success for any application.
Waters’ full portfolio of MS innovations will be on display in
Atlanta, including the ASMS debut of the BioAccord™ LC-MS System
for Biopharmaceuticals, a purposefully designed solution that
expands access to high-resolution time-of-flight mass spectrometry,
including multi attribute monitoring capabilities, to more
scientists who are analyzing critical quality attributes.
“The introduction of the Cyclic IMS and SYNAPT XS systems is an
exciting manifestation of our increased R&D investments at
Waters, particularly in mass spectrometry technologies,” said Chris
O’Connell, Chairman and CEO of Waters Corporation. “These powerful
new technologies add to our portfolio of recent Mass Spectrometry
introductions such as the BioAccord System, Vion™ IMS QTof and the
ACQUITY™ QDa™ Detector, and signal the accelerating pace of our
exciting overall new product development cycle at Waters.”
New SELECT SERIES Cyclic IMS
Ion mobility mass spectrometry is a proven technique to rapidly
obtain information for structural elucidation and significantly
enhances system peak capacity. Waters is a champion of this
technology and leads the way in instrument research and
development. The SELECT SERIES Cyclic IMS takes ion mobility
separations to a new level by replacing the traditional linear ion
mobility region with a novel compact cyclic ion guide. Ions
traverse around the ion guide and with every pass, greater ion
mobility resolution is achieved. The innovative cyclic device
provides scalable, high-resolution ion mobility separations and
introduces the unique ability to perform ion mobility/ion mobility
and IMSn experiments, extending the benefits of routine ion
mobility.
“The improvements in ion mobility resolving power combined with
the flexibility of the instrument which allows IMSn experiments, to
select sub populations for further study, will be transformative
for our work,” said Dr. Kostas Thalassinos, a leading researcher at
University College London, who has recently published results
describing the benefits of the system for protein structural
studies.
The Journal Analytical Chemistry documented the effectiveness
and power of the cyclic IMS instrument in a recent article titled:
A Cyclic Ion Mobility – Mass Spectrometry System.
New Research-Grade SYNAPT XS System
The SYNAPT XS is the newest iteration in the SYNAPT family of
research grade mass spectrometers. The SYNAPT family is known and
acclaimed for both its flexibility and its unique T-Wave IMS
configuration, which significantly extends the power of
high-resolution analysis. IMS capability on the SYNAPT increases
the extent and confidence with which a scientist can profile
complex mixtures and characterize complex molecules, and
dramatically enhances sample definition.
The inherent power of SYNAPT is enhanced in the new SYNAPT XS
with new technology building blocks that provide increased
sensitivity for challenging compounds while further improving the
levels of analytical robustness at far superior mass resolution
than previous models. In addition, complementary modes of operation
that increase analytical peak capacity providing ‘clean and clear’
fragmentation data provide a truly unique investigative toolbox for
the interrogation of complex mixtures.
“Focused on discovery and characterization applications, the new
SYNAPT XS provides enhanced levels of sensitivity and mass
resolution combined with highly reproducible CCS measurements” said
Joanne Ballantyne, PhD, Principal Marketing Manager Mass
Spectrometry Systems. “Unlike competitors’ systems with restricted
inlet options, scan function limitations, or requiring multiple
mass spectrometers, only Waters offers an all-encompassing
high-performing LC-MS solution which, by design, provides greater
freedom of analytical choice to support scientific creativity.”
BioAccord LC-MS System for Biopharmaceutical
Applications
The BioAccord LC-MS System for Biopharmaceuticals continues to
address critical needs of biopharmaceutical customers by expanding
access to high-resolution time-of-flight mass spectrometry
capabilities to more scientists.
“Rollout of the BioAccord System continues to excite our
biopharmaceutical customers as they contend with increasing
complexity of their molecules and business models,” said Mike
Wilson, Director, Product Marketing Mass Spectrometry Systems. “The
BioAccord System is a holistic, purposefully designed, compliant
LC-MS biopharmaceutical solution with intelligence built into our
newly designed, ACQUITY™ RDa Detector. Given the inherent
complexity of biologic molecules, the BioAccord System promises to
move routine monitoring out of centralized MS labs and into the
hands of more scientists by enabling more effective and
reproducible analysis of biotherapeutic protein attributes across
development and within quality control organizations."
Waters Presentations at ASMS 2019
Waters’ scientists will present more than 70 oral presentations
and posters at ASMS many of which demonstrate the capability of ion
mobility mass spectrometry for characterizing intact proteins,
protein complexes, peptide mixtures, saponins, oligonucleotides,
and lubricant oils.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass
spectrometry, and thermal analysis innovations serving the life,
materials, and food sciences for more than 60 years. With
approximately 7,200 employees worldwide, Waters operates directly
in 35 countries, including 15 manufacturing facilities, and with
products available in more than 100 countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190530005814/en/
Jeff Tarmy508-482-2268jeff_tarmy@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Sep 2023 to Sep 2024